Enterolactone

Research use only, not for human use.

Enterolactone is a useful organic compound for research related to life sciences.

Enterolactone is a useful organic compound for research related to life sciences.

Enterolactone (25-75 μM; 48 hours) arrests the growth of MDA-MB-231 breast cancer cells in the ‘S’ phaseEnterolactone (25-75 μM; 15 hours) triggers apoptosis in MDA-MB-231 breast cancer cells via caspase-3 activation.Enterolactone inhibits TGF-β-induced migration of MDA-MB-231 breast cancer cells. Enterolactone inhibits TGF-β-induced invasion of MDA-MB-231 breast cancer cells through ECM. Enterolactone inhibits the TGF-β-induced EMT program in MDA-MB-231 breast cancer cells. Enterolactone reduces the formation of actin stress fibers by inhibiting the expression of CD44 and MAPK-p38. Enterolactone inhibits the ERK/NF-κB/Snail signaling pathway to revert TGF-β-induced EMT in MDA-MB-231 cells. Cell Viability Assay Cell Line:MDA-MB-231 cells Concentration:25, 50, 75 μM Incubation Time:48 hours Result:There was a non-significant increase (~24%) in the S phase population following treatment with 25 μM EL, whereas there were significant increases (~34% and ~39%) following treatment with 50 and 75 μM EL, respectively.

——

——

Others

Other Targets

——

——

——

78473-71-9

298.3

C18H18O4

>98% (HPLC)

——

——

——

(-20℃)

With Ice Pack

≥ 2 years